M. Hochberg

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Marcc . Hochberg, M C Hochberg, M. Hochberg, Mark Hochberg, Marc C. Hochberg, Marc C Hochberg, March Hochberg, M.c. Hochberg, M Hochberg, M. C. Hochberg, Marc Hochberg
Publication record
723 papers · 92,113 citations · H-index 128

PAPERS

Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study.
202316 citationsauthor #4
Role of imaging for eligibility and safety of a-NGF clinical trials
20237 citationsauthor #2
Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab.
202320 citationsauthor #5
Evaluation of S201086/GLPG1972, an ADAMTS-5 inhibitor, for the treatment of knee osteoarthritis in ROCCELLA: a phase 2 randomized clinical trial.
202333 citationsauthor #13
Tennis Is Not Associated With Symptomatic Radiographic Knee Osteoarthritis: Data From The Osteoarthritis Initiative
20230 citationsauthor #7
Predictors of mobility status one year post hip fracture among community-dwelling older adults prior to fracture: A prospective cohort study.
20232 citationsauthor #4
OP0151 DULOXETINE PLUS EXERCISE FOR KNEE OSTEOARTHRITIS AND DEPRESSION (DEKODE)
20230 citationsauthor #11
A feasibility study of combined treatment using aerobic exercise and duloxetine in adults with symptomatic knee osteoarthritis and comorbid depression
20230 citationsauthor #11
POS1138 PERSISTENCY OF DEPRESSIVE SYMPTOMS AND PHYSICAL PERFORMANCE IN KNEE OSTEOARTHRITIS
20221 citationsauthor #9
Seminars in Arthritis and Rheumatism moves to online-only publication.
20221 citationsauthor #1
Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development - Should future studies focus on disease activity, rather than status?
20228 citationsauthor #3
Comparison of Evaluation Metrics of Deep Learning for Imbalanced Imaging Data in Osteoarthritis Studies
202220 citationsauthor #9
Effect of multicomponent home-based training on gait and muscle strength in older adults after hip fracture surgery: a single site randomized trial.
20228 citationsauthor #6
Tibiofemoral knee osteoarthritis progresses symmetrically by knee compartment in the GOGO cohort
20223 citationsauthor #8
Long‐term sex differences in all‐cause and infection‐specific mortality post hip fracture
202217 citationsauthor #6
ASSOCIATION OF PERSISTENT DEPRESSIVE SYMPTOMS WITH PHYSICAL ACTIVITY IN KNEE OSTEOARTHRITIS
20220 citationsauthor #6
GARDENING/YARDWORK IS NOT ASSOCIATED WITH NEW KNEE PAIN OR DISEASE PROGRESSION OVER 48 MONTHS IN THOSE WITH KNEE OSTEOARTHRITIS: DATA FROM THE OSTEOARTHRITIS INITIATIVE
20220 citationsauthor #7
Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach
202214 citationsauthor #12
Prevalence, Incidence, and Progression of Radiographic and Symptomatic Hand Osteoarthritis: The Osteoarthritis Initiative
202231 citationsauthor #10
Association Between Walking for Exercise and Symptomatic and Structural Progression in Individuals With Knee Osteoarthritis: Data From the Osteoarthritis Initiative Cohort
202232 citationsauthor #9
Contribution of Common Genetic Variants to Risk of Early-Onset Ischemic Stroke
202221 citationsauthor #36
FDA/Arthritis Foundation osteoarthritis drug development workshop recap: Assessment of long-term benefit.
202225 citationsauthor #9
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2021): ESCEO Symposium Abstracts
20210 citationsauthor #9
Effect of Multicomponent Home-Based Training on Gait and Muscle Strength Performance in Older Adults With Hip Fracture
20211 citationsauthor #5
Medical overuse of therapies and diagnostics in rheumatology
20216 citationsauthor #9
Differential misclassification of cognitive impairment by sex among hip fracture patients
20215 citationsauthor #6
Efficacy and safety of s201086/GLPG1972, an ADAMTS-5 inhibitor, in patients with knee osteoarthritis: roccella, a 52-week, randomized, double-blind, dose-ranging phase 2 study
20216 citationsauthor #13
Response letter to the Editor.
20210 citationsauthor #10
A Phase 2b Randomized Trial of Lorecivivint, a Novel Intra-articular CLK2/DYRK1A Inhibitor and Wnt Pathway Modulator for Knee Osteoarthritis.
202188 citationsauthor #13
EFFICACYAND SAFETYFROMAPHASE 2B TRIALOF SM04690, A NOVEL, INTRA-ARTICULARWNT PATHWAY INHIBITOR FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE
20210 citationsauthor #11
Non-surgical management of hip and knee osteoarthritis; comparison of ACR/AF and OARSI 2019 and VA/DoD 2020 guidelines
202145 citationsauthor #2
The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial.
202142 citationsauthor #9
Pain reduction in either the knee or the hip with subcutaneous tanezumab: a pooled analysis in patients with moderate to severe osteoarthritis and a history of inadequate response to other analgesics
20210 citationsauthor #1
Long‐Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial
202163 citationsauthor #1
Did COVID-19 impact osteoarthritis – clinical perspective?
202114 citationsauthor #3
Change in vertebral strength and bone mineral density in men and women over the year post-hip fracture: a subgroup analysis
20214 citationsauthor #5
Osteoarthritis Research Society International (OARSI): Past, present and future
20218 citationsauthor #10
Sex Differences in Recovery Across Multiple Domains among Older Adults with Hip Fracture.
202121 citationsauthor #3
Sports with a Bat or Racket are Not Associated with Thumb-base Osteoarthritis.
20214 citationsauthor #11
Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study
202189 citationsauthor #2
Depressive symptom heterogeneity among older adults after hip fracture.
20216 citationsauthor #7
Precision medicine in osteoarthritis: not yet ready for prime time
20209 citationsauthor #3
Lorecivivint, a Novel Intraarticular CDC‐like Kinase 2 and Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial
2020120 citationsauthor #12
Predicting knee replacement in participants eligible for disease-modifying osteoarthritis drug treatment with structural endpoints.
202016 citationsauthor #6
Evaluating the structural effects of intra-articular sprifermin on cartilage and non-cartilaginous tissue alterations, based on sqMRI assessment over two years.
202020 citationsauthor #5
Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines
2020434 citationsauthor #7
Disease modification in osteoarthritis; pathways to drug approval
202040 citationsauthor #8
Depression Subtypes in Individuals With or at Risk for Symptomatic Knee Osteoarthritis
202020 citationsauthor #8
Evidence that Swimming May Be Protective of Knee Osteoarthritis: Data from the Osteoarthritis Initiative
202013 citationsauthor #9
Neurocognitive measures predict voluntary stepping performance in older adults post-hip fracture.
20202 citationsauthor #7
An integrated safety analysis of lorecivivint, a novel, intra-articular CLK/DYRK1A inhibitor that modulates the WNT pathway, in subjects with knee osteoarthritis
20201 citationsauthor #7
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee
20202,565 citationsauthor #3
Relationship Between Depression and Disease Activity in United States Veterans With Early Rheumatoid Arthritis Receiving Methotrexate
20207 citationsauthor #7
Lorecivivint, an intra-articular potential disease-modifying osteoarthritis drug
202020 citationsauthor #3
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition.
20205 citationsauthor #22
Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial
202062 citationsauthor #6
Comparing Longitudinal Sarcopenia Trends by Definitions Across Men and Women After Hip Fracture
202012 citationsauthor #7
Intra-articular Corticosteroid Injections in the Hip and Knee: Perhaps Not as Dangerous as They Want You to Believe?
202010 citationsauthor #4
Plane Dependent Subject-Specific Neuromuscular Training for Knee Rehabilitation
20203 citationsauthor #5
Long-term efficacy and safety of intra-articular sprifermin in patients with knee osteoarthritis: results from the 5-year forward study
20206 citationsauthor #2
Association between disease progression and depression onset in persons with radiographic knee osteoarthritis.
202025 citationsauthor #8
OP0188 INTEGRATED SAFETY SUMMARY OF THE NOVEL, INTRA-ARTICULAR AGENT LORECIVIVINT (SM04690), A CLK/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, IN SUBJECTS WITH KNEE OSTEOARTHRITIS
20206 citationsauthor #8
Genome-wide meta-analysis identified novel variant associated with hallux valgus in Caucasians
202010 citationsauthor #10
Football Increases Future Risk for Symptomatic Radiographic Knee Osteoarthritis.
20208 citationsauthor #9
Sex Differences in Bone-Active Medication Utilization Before and During the Year After Hip Fracture
20200 citationsauthor #4
Walking for exercise may be symptom and structure modifying for those with established osteoarthritis and with varus alignment - data from the osteoarthritis initiative
20200 citationsauthor #8
Secondary Fracture Prevention: Consensus Clinical Recommendations From a Multistakeholder Coalition.
202037 citationsauthor #22
Depression moderates analgesic effectiveness among individuals with radiographic knee osteoarthritis
20201 citationsauthor #8
Type 2 diabetes mellitus and osteoarthritis.
2019209 citationsauthor #4
OP0226 SOLID TUMOUR OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY
20194 citationsauthor #11
Trunk Muscle Composition 2 Months After Hip Fracture: Findings From the Baltimore Hip Studies.
20198 citationsauthor #8
Serum 25(OH)D is associated with an altered bone turnover marker response after a hip fracture
201913 citationsauthor #4
Comparison of intra-articular sham and vehicle injection from a phase 2b trial of SM04690, a small-molecule Wnt inhibitor, for knee osteoarthritis
20193 citationsauthor #7
Development and validation of risk stratification trees for incident slow gait speed in persons at high risk for knee osteoarthritis
20197 citationsauthor #6
The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis
2019145 citationsauthor #25
SAT-382 Glucocorticoid Tapering in Monthly 1-mg Decrements Does Not Result in Clinically Manifest Adrenal Insufficiency in Patients with Rheumatoid Arthritis: Learnings from the Phase 3/4 SEMIRA Study
20190 citationsauthor #4
Differences in evidence‐based osteoporosis medication use between elderly men and women enrolled in Medicare Part D
20193 citationsauthor #6
THU0128 GLUCOCORTICOID TAPERING IN MONTHLY 1-MG DECREMENTS DOES NOT RESULT IN CLINICALLY MANIFEST ADRENAL INSUFFICIENCY IN PATIENTS WITH RHEUMATOID ARTHRITIS: LEARNINGS FROM THE PHASE 3/4 SEMIRA STUDY
20191 citationsauthor #4
THU0449 EFFECT MODERATION OF ANALGESIC TREATMENT OUTCOMES BY DEPRESSION IN PERSONS WITH OR AT-RISK FOR SYMPTOMATIC KNEE OSTEOARTHRITIS
20190 citationsauthor #8
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition
2019198 citationsauthor #21
THU0414 COMPARISON OF INTRA-ARTICULAR SHAM AND VEHICLE INJECTIONS FROM A PHASE 2B TRIAL OF SM04690, A SMALL-MOLECULE WNT PATHWAY INHIBITOR FOR KNEE OSTEOARTHRITIS
20190 citationsauthor #7
Differences in geometric strength at the contralateral hip between men with hip fracture and non-fractured comparators.
20191 citationsauthor #9
MANAGEMENT OF OSTEOARTHRITIS IN DIABETIC PATIENTS
20191 citationsauthor #8
Prediction models for incident slow gait speed over 10 years in persons at high risk for knee osteoarthritis
20190 citationsauthor #6
Efficacy and safety from a phase 2B trial of SM04690, a novel, intra-articular, WNT pathway inhibitor for the treatment of osteoarthritis of the knee
201915 citationsauthor #10
THU0458 EFFICACY AND SAFETY FROM A PHASE 2B TRIAL OF SM04690, A NOVEL INTRA-ARTICULAR WNT PATHWAY INHIBITOR FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE
201910 citationsauthor #10
The Relationship Between Alcohol Consumption and Hip Fracture Recovery Among Older Adults
20192 citationsauthor #5
Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study
201964 citationsauthor #3
FRI0118 INFECTION OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY
20193 citationsauthor #11
METABOLOMICS IN MEN WITH DISTINCT INFLAMMATION TRAJECTORIES FOLLOWING HIP FRACTURE REVEAL RESPONSE MECHANISMS
20190 citationsauthor #7
Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial.
2019282 citationsauthor #1
Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017
201926 citationsauthor #25
Interleukin 1 receptor antagonist (IL1RN) gene variants predict radiographic severity of knee osteoarthritis and risk of incident disease
201944 citationsauthor #10
Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis
201946 citationsauthor #7
OP0010 CARTILAGE THICKNESS MODIFICATION WITH SPRIFERMIN IN KNEE OSTEOARTHRITIS PATIENTS TRANSLATES INTO SYMPTOMATIC IMPROVEMENT OVER PLACEBO IN PATIENTS AT RISK OF FURTHER STRUCTURAL AND SYMPTOMATIC PROGRESSION: POST-HOC ANALYSIS OF THE PHASE II FORWARD TRIAL
201910 citationsauthor #9
Overweight and Obese Have Similar Burden of Hip Fracture as Normal Weight Older Adults
20191 citationsauthor #3
Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials
201920 citationsauthor #3
Osteoporosis Medication Use: A Comparison of Elderly Females Living in Long-term Care Facilities Versus Community Dwellers.
20194 citationsauthor #6
SP0013 GROWTH FACTORS AND CARTILAGE: FROM MECHANISMS TO DMOADS
20190 citationsauthor #1
Pain severity as a mediator of the association between depressive symptoms and physical performance in knee osteoarthritis.
201828 citationsauthor #7

TIMELINE

1974 11 citations

1976 25 citations

1977 94 citations

1978 51 citations

1982 65 citations

1983 58 citations

1984 692 citations

1985 384 citations

1986 6,903 citations

1987 37 citations

1988 217 citations

1989 638 citations

1990 221 citations

1991 605 citations

1992 5,995 citations

1993 816 citations

1994 95 citations

1995 3,695 citations

1996 1,478 citations

1997 430 citations

1998 3,744 citations

1999 1,660 citations

2000 10,093 citations

2001 1,930 citations

2002 2,216 citations

2003 1,904 citations

2004 6,719 citations

2005 2,864 citations

2006 1,646 citations

2007 3,691 citations

2008 11,300 citations

2009 1,355 citations

2010 3,790 citations

2011 1,293 citations

2012 3,745 citations

2013 1,068 citations

2014 1,669 citations

2015 2,264 citations

2016 635 citations

2017 190 citations

2018 597 citations

2019 1,120 citations

2020 3,452 citations

2021 402 citations

2022 181 citations

2023 78 citations

Unknown 17 citations

M. Hochberg

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT